Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits

Area of Science:

• Cardiology
• Endocrinology
• Mitochondrial Biology

Background:

• Diabetic cardiomyopathy is characterized by left ventricular diastolic dysfunction.
• Mitochondrial dysfunction is an early event in diabetic myocardium.
• Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Purpose of the Study:

• To investigate if alogliptin prevents diastolic dysfunction in diabetic rabbits.
• To assess alogliptin's effect on left ventricular mitochondrial function and structure.
• To explore the underlying mechanisms of alogliptin's cardioprotective effects.

Main Methods:

• Alogliptin (12.5 mg/kg/day for 12 weeks) was administered to alloxan-induced diabetic rabbits.
• Echocardiographic and hemodynamic assessments were performed.
• Mitochondrial morphology, function, reactive oxygen species (ROS) production, and biogenesis signaling pathways were analyzed.

Main Results:

• Diabetic rabbits showed left ventricular hypertrophy, diastolic dysfunction, and impaired mitochondrial function (increased ROS, depolarization).
• Alogliptin treatment alleviated cardiac remodeling, interstitial fibrosis, and diastolic dysfunction.
• Alogliptin improved mitochondrial function, reduced ROS, and enhanced mitochondrial biogenesis via the PGC-1α/NRF1/Tfam pathway.

Conclusions:

• Alogliptin prevents cardiac diastolic dysfunction in diabetic rabbits.
• Improved mitochondrial function and enhanced mitochondrial biogenesis are key mechanisms.
• Alogliptin demonstrates potential as a therapeutic agent for diabetic cardiomyopathy.